Researchers have developed a high-resolution mass spectrometry technique to help predict response to azacitidine (Vidaza) therapy in patients with conditions such as myelodysplastic syndrome (MDS). The AZA-MS method, as described in the latest issue of Leukemia, can directly quantify cellular uptake of azacitidine and its incorporation into both DNA and RNA. The research found two ...
Tool predicts non-responders in MDS
By Mardi Chapman
19 Jan 2018